Pharmacological and non-pharmacological strategies targeting HIF signaling and hypoxia tolerance: opportunities and limitations for personalized interventions
Abstract
For acute mountain sickness prevention and the treatment of respiratory, cardiovascular, and nervous system diseases, pharmacological (prolyl hydroxylase domain inhibitors, plant extracts, erythrocyte pyruvate kinase activators, and hemoglobin oxygen affinity allosteric activators) and non-pharmacological approaches (hypoxic training and hypoxic therapy) are used. However, drug use is limited by their toxicity, low bioavailability, and prolonged hypoxia-inducible factor – HIF – activation risks, which may lead to tumor growth initiation, as well as cardiovascular and metabolic disorders. At the same time, the effectiveness of hypoxic exposure varies and depends on the regimen, sex, age, and initial organism tolerance. Among athletes, the live high–train low strategy is the most commonly used, whereas for healthy volunteers and individuals in extreme professions, regimen selection based on a preliminary determination of the organism’s hypoxia tolerance is required. Moderate hypoxic exposure may improve clinical outcomes in patients with cardiovascular and neurological diseases; however, variability in effects is associated with the absence of initial consideration of organism oxygen deficiency tolerance in studies. It determines the effectiveness of hypoxia adaptation and is influenced by genetic, epigenetic, and phenotypic factors, with HIF activation being the most significant. In this review, HIF induction and hypoxic exposure are considered approaches to increase organismal hypoxia tolerance, and the need for a personalized approach, considering them in interventions on healthy individuals and patients, is substantiated.
Related
- Interventions for Cognitive Impairment in Type 2 Diabetes Mellitus: An Umbrella Review of Pharmacological and Lifestyle Strategies, Mechanisms, and Clinical Implications
- Modeling human neurodegeneration with iPSCs: opportunities, limitations, and the challenge of aging
- Comparative efficacy of non-pharmacological interventions for amnestic mild cognitive impairment: a network meta-analysis
- Home-based non-pharmacological interventions for cognition and diabetes self-management in adults with type 2 diabetes: a systematic review
- A systematic review and meta-analysis of the effects of non-pharmacological interventions in improving psychological status and sleep quality among hemodialysis patients
BibTeX
@article{kirillova2026pharmacological,
title = {{Pharmacological and non-pharmacological strategies targeting HIF signaling and hypoxia tolerance: opportunities and limitations for personalized interventions}},
author = {Maria Kirillova and Nikolai Fokichev and Dzhuliia Dzhalilova},
journal = {Frontiers in Public Health},
year = {2026},
month = nov,
doi = {10.3389/fpubh.2026.1943929},
url = {https://www.frontiersin.org/articles/10.3389/fpubh.2026.1943929},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Pharmacological and non-pharmacological strategies targeting HIF signaling and hypoxia tolerance: opportunities and limitations for personalized interventions
AU - Maria Kirillova
AU - Nikolai Fokichev
AU - Dzhuliia Dzhalilova
PY - 2026
DA - 2026/11/02
JO - Frontiers in Public Health
DO - 10.3389/fpubh.2026.1943929
UR - https://www.frontiersin.org/articles/10.3389/fpubh.2026.1943929
AB - For acute mountain sickness prevention and the treatment of respiratory, cardiovascular, and nervous system diseases, pharmacological (prolyl hydroxylase domain inhibitors, plant extracts, erythrocyte pyruvate kinase activators, and hemoglobin oxygen affinity allosteric activators) and non-pharmacological approaches (hypoxic training and hypoxic therapy) are used. However, drug use is limited by their toxicity, low bioavailability, and prolonged hypoxia-inducible factor – HIF – activation risks, which may lead to tumor growth initiation, as well as cardiovascular and metabolic disorders. At the same time, the effectiveness of hypoxic exposure varies and depends on the regimen, sex, age, and initial organism tolerance. Among athletes, the live high–train low strategy is the most commonly used, whereas for healthy volunteers and individuals in extreme professions, regimen selection based on a preliminary determination of the organism’s hypoxia tolerance is required. Moderate hypoxic exposure may improve clinical outcomes in patients with cardiovascular and neurological diseases; however, variability in effects is associated with the absence of initial consideration of organism oxygen deficiency tolerance in studies. It determines the effectiveness of hypoxia adaptation and is influenced by genetic, epigenetic, and phenotypic factors, with HIF activation being the most significant. In this review, HIF induction and hypoxic exposure are considered approaches to increase organismal hypoxia tolerance, and the need for a personalized approach, considering them in interventions on healthy individuals and patients, is substantiated.
SN - 2296-2565
ER -